What Is Endocrine Cancer? Types, Symptoms, and Treatment

Endocrine cancer is any malignancy that arises in the hormone-producing glands of the body, including the thyroid, adrenal glands, pancreas, pituitary gland, and parathyroid glands. Because these glands regulate everything from metabolism and blood sugar to stress responses and growth, the cancers that develop in them often cause unusual hormonal symptoms long before a lump becomes noticeable. The category is broader than most people realize, ranging from slow-growing tumors that can be monitored for years to aggressive cancers that demand immediate, multi-pronged treatment.

Where Endocrine Cancers Develop

The endocrine system is scattered across the body, and cancers can crop up at any of its nodes. The most common site is the thyroid, a butterfly-shaped gland in the neck. Thyroid cancers include papillary (the most frequent and usually the most treatable), follicular, medullary, and anaplastic types. Research into the genetic changes behind these cancers shows a stepwise progression: early mutations in genes that promote cell growth lead to well-differentiated cancers like papillary and follicular types, while later mutations, particularly loss of the p53 tumor-suppressor gene, can push a tumor toward the far more dangerous anaplastic form.¹ Genomic studies confirm this multi-step model, finding that early driver mutations (often in BRAF or RAS genes) are shared across differentiated and undifferentiated thyroid cancers, with additional late-stage mutations in TP53 and the TERT promoter accumulating as the tumor becomes more aggressive.²

The adrenal glands, perched atop the kidneys, give rise to two main cancer types depending on which layer is affected. Adrenocortical carcinoma develops in the outer cortex, which produces cortisol and sex hormones. It often shows up with signs of cortisol excess or masculinizing features from overproduction of androgens.³ Pheochromocytoma, in contrast, arises from the inner medulla and pumps out adrenaline-like hormones, causing dramatic spikes in blood pressure and heart rate.

Pancreatic neuroendocrine tumors (sometimes called islet-cell tumors) are rarer than the common pancreatic adenocarcinoma but behave quite differently. They are classified as functioning or nonfunctioning based on whether they secrete enough hormone to produce symptoms. Insulinomas, gastrinomas, and glucagonomas are the most common functioning types.⁴ In a notable quirk, some pancreatic endocrine tumors shift their hormonal output over time: a study tracking over 350 confirmed cases found that about 7 percent developed elevated levels of a different hormone years after the initial diagnosis, sometimes with life-threatening consequences like gastrointestinal perforation.⁵

Pituitary tumors are among the most common intracranial growths. Roughly half of them actively secrete hormones, most often prolactin, growth hormone, or the hormone that drives cortisol production.⁶ While almost all pituitary tumors are benign under a microscope, the hormonal havoc they cause and the pressure they exert on nearby brain structures (including the optic nerves) make them medically serious.⁷ Parathyroid cancer is the rarest of the bunch, but it deserves mention because it drives calcium levels dangerously high, a condition that affects the heart, kidneys, and bones.

How Endocrine Cancers Make Themselves Known

The tricky part about endocrine cancers is that their symptoms often mimic more common, benign conditions. A functioning pituitary tumor secreting too much growth hormone causes enlarged hands and coarsened facial features over years, changes that are easy to dismiss as aging. Adrenocortical carcinoma producing cortisol leads to weight gain, high blood sugar, and easy bruising, all of which could be blamed on a dozen other causes. Insulinomas cause episodes of dangerously low blood sugar, with shakiness and confusion that get attributed to missed meals. Nonfunctioning tumors tend to stay silent until they grow large enough to press on something, producing symptoms from compression of neighboring organs or nerves rather than from hormonal excess.⁸

One of the more dramatic symptom clusters in endocrine oncology is carcinoid syndrome, which develops in patients with neuroendocrine tumors (usually of the gut) that release enough serotonin and other active substances to reach the bloodstream in significant quantities. The classic features are flushing, diarrhea, abdominal pain, and wheezing.⁹ Over time, serotonin stimulates fibrosis, particularly in the heart, leading to carcinoid heart disease. This predominantly damages right-sided heart valves, with tricuspid regurgitation showing up in virtually all affected patients in one study. The same study found that patients who developed heart involvement had serotonin levels roughly twice as high as those who did not.¹⁰

Parathyroid carcinoma produces its own distinct complication: severe hypercalcemia. Among cancers that raise calcium levels, parathyroid carcinoma does so through direct overproduction of parathyroid hormone, which is mechanistically different from the calcium elevation caused by other malignancies (where bone metastases or secretion of a parathyroid-hormone-like protein are usually responsible).¹¹ The resulting high calcium levels cause kidney stones, bone pain, muscle weakness, confusion, and heart rhythm problems.

Hereditary Syndromes That Raise the Risk

Most endocrine cancers arise sporadically, but a meaningful minority are linked to inherited genetic syndromes, and identifying these families early can be lifesaving. Multiple endocrine neoplasia type 1 (MEN1) predisposes people to tumors of the pituitary, parathyroid, and pancreas. The syndrome is caused by mutations in the MEN1 gene, of which more than 1,300 distinct variants have been catalogued. Most of these mutations are unique to a single family.¹²

Multiple endocrine neoplasia type 2 (MEN2) revolves around a different gene entirely: the RET proto-oncogene. Specific RET mutations predict both the onset and severity of medullary thyroid cancer, the defining feature of MEN2. Genetic testing for RET mutations was one of the first examples of direct gene-based risk assessment in oncology, allowing at-risk family members to undergo surveillance or even preventive thyroidectomy based on which mutation they carry.¹³

A third hereditary pathway involves mutations in the SDH genes, which predispose to pheochromocytoma and paraganglioma. These tumors appear especially aggressive in younger patients with SDH mutations, showing higher rates of metastatic disease at diagnosis. Children and adolescents with pheochromocytomas have a higher likelihood of carrying a familial SDH mutation than adults do.¹⁴ For all of these syndromes, the practical takeaway is the same: if you have a first-degree relative with an endocrine tumor, genetic counseling is worth pursuing.

How Endocrine Cancers Are Diagnosed

Diagnosis usually involves some combination of blood tests, imaging, and biopsy. Blood and urine tests can detect the hormonal signatures of functioning tumors: elevated insulin, gastrin, cortisol, catecholamines, or calcium, depending on the gland involved. For neuroendocrine tumors specifically, chromogranin A is a widely used biomarker. It has been a standard part of managing neuroendocrine tumors of the gut and pancreas for years, although it is not perfect and can be influenced by other conditions.¹⁵ Compared to older markers like urinary 5-HIAA (a serotonin breakdown product), chromogranin A tends to be more broadly useful since 5-HIAA is sensitive to certain foods and medications.¹⁶

On the imaging side, a specialized PET scan using a radiotracer called 68Ga-DOTATATE has become the preferred method for evaluating well-differentiated neuroendocrine tumors. It works by binding to somatostatin receptors that these tumors express in abundance, lighting them up with high precision. National guidelines now include this scan as an appropriate test for managing neuroendocrine tumors, and studies have shown it outperforms older imaging options like Octreoscan and MIBG scintigraphy in detecting lesions.¹⁷ It also helps identify patients who are candidates for a targeted radiation treatment that exploits the same receptor system, which makes the scan both diagnostic and treatment-guiding.¹⁸

Treatment Approaches

Treatment for endocrine cancers varies enormously by type, stage, and how fast the tumor is growing. Surgery is the cornerstone for most localized endocrine tumors. For thyroid cancer, that typically means removing part or all of the thyroid gland, often followed by radioactive iodine therapy for differentiated types. Radioactive iodine works because normal and well-differentiated thyroid cancer cells absorb iodine through a protein called the sodium iodide symporter. After thyroidectomy, a dose of radioactive iodine can seek out and destroy residual cancer cells.¹⁹

The catch is that some thyroid cancers stop absorbing iodine as they become less differentiated, a problem called radioactive iodine refractoriness. Up to 60 percent of papillary thyroid carcinomas carry the BRAF V600E mutation, which is strongly linked to reduced iodine uptake and poorer differentiation.²⁰ For patients whose tumors no longer respond to radioactive iodine, targeted drugs called kinase inhibitors have filled the gap. Lenvatinib, for instance, extended the time before cancer progression to a median of about 18 months compared to roughly 4 months with placebo in a trial of advanced, iodine-resistant thyroid cancer, with about two-thirds of patients seeing their tumors shrink.²¹

For pancreatic neuroendocrine tumors, sunitinib (another kinase inhibitor) has been approved and roughly doubled the time before disease progression compared to placebo.²² Surgery also plays an important role even in metastatic neuroendocrine disease. When liver metastases from neuroendocrine tumors can be surgically reduced by at least 70 percent, patients enjoy meaningfully longer survival and better symptom control.²³ Complete removal of all metastatic disease, when possible, is associated with the longest survival, with one analysis finding median survival exceeding nine years in that group.²⁴

A newer treatment called peptide receptor radionuclide therapy (PRRT) uses the same somatostatin receptors targeted by the 68Ga-DOTATATE scan. A radioactive compound, usually lutetium-177 linked to a somatostatin analog, is injected and homes in on tumor cells expressing those receptors, delivering targeted radiation directly to the cancer.²⁵ A meta-analysis of studies using this approach found that roughly 78 to 79 percent of patients achieved disease control, with side effects that were generally manageable, mainly fatigue and nausea.²⁶

Immunotherapy, a mainstay for many solid tumors, has had a more limited role in endocrine cancers so far. The most promising results have been in anaplastic thyroid cancer, the most aggressive thyroid subtype, where checkpoint inhibitors like pembrolizumab have shown better response rates in tumors with high PD-L1 expression and a high burden of genetic mutations.²⁷ Preclinical work in mice has also shown that combining a BRAF inhibitor with a PD-L1 antibody produces far greater tumor shrinkage than either drug alone, a combination approach that may eventually translate to human trials for aggressive thyroid cancers.²⁸

How Tumor Grade Shapes the Prognosis

If you are diagnosed with a neuroendocrine tumor, one of the first things the pathologist will report is its grade, which reflects how quickly the tumor cells are dividing. The standard way to measure this is by counting the fraction of tumor cells expressing a protein called Ki-67. This index is mandatory in the workup of gut and pancreatic neuroendocrine tumors and has well-documented power to predict outcomes.²⁹ In practice, tumors are split into low-grade (G1), intermediate-grade (G2), and high-grade (G3), and the grade strongly influences which treatments are offered.

Even within a single grade category, the details matter. Recent work looking at G2 tumors found that the pattern of Ki-67 staining (whether dividing cells are scattered diffusely throughout the tumor or clustered in a few hotspots) predicts survival independently. Patients whose G2 tumors had a diffuse pattern of proliferation survived significantly less time than those with a focal pattern.³⁰ This kind of nuance is pushing pathology toward more sophisticated analysis tools and is a reminder that the grade printed on a report is not always the final word on aggressiveness.

Risk Factors for Endocrine Cancers

For thyroid cancer, the best-established environmental risk factor is childhood exposure to ionizing radiation.³¹ This includes radiation from nuclear fallout, accidental exposures, and medical radiation directed at the head and neck during childhood. Exposure to certain organic and inorganic chemical toxicants is also recognized as a public health concern for thyroid cancer risk, though the evidence for individual chemicals is less definitive than it is for radiation.³²

For other endocrine cancers, the risk-factor picture is sparser. Pheochromocytoma and paraganglioma have the strongest hereditary component, as noted above. Pancreatic neuroendocrine tumors lack a single dominant environmental risk factor, and most arise without an obvious cause. Obesity and diabetes have been loosely associated with adrenocortical carcinoma, but these links are weaker and harder to study given how rare the tumor is. The practical message is that most endocrine cancers cannot be prevented through lifestyle changes alone, though minimizing unnecessary radiation exposure during childhood remains prudent advice.

Living With the Aftermath of Treatment

Surviving an endocrine cancer often means managing lifelong hormonal consequences of treatment. The clearest example is thyroid cancer: total or near-total thyroidectomy eliminates the body’s ability to produce thyroid hormone, making daily replacement therapy an unavoidable, permanent requirement. Beyond simple replacement, many thyroid cancer survivors take higher doses of thyroid hormone to suppress any remaining cancer cells that are sensitive to growth signals from the pituitary gland. Damage to the parathyroid glands during thyroid surgery is another known complication, and patients with permanent loss of parathyroid function need ongoing calcium and vitamin D supplementation.³³

Patients treated for pituitary tumors face their own set of follow-up challenges. Surgery or radiation directed at the pituitary can leave it partially or fully unable to produce its hormones, requiring replacement of cortisol, thyroid hormone, sex hormones, or growth hormone depending on which cell populations are lost. For adrenal cancers, removal of one or both adrenal glands may necessitate lifelong cortisol replacement, and patients need to carry emergency medication for situations where the body demands a surge of cortisol (like surgery or severe illness) that the remaining gland cannot deliver.

Neuroendocrine tumor survivors receiving ongoing somatostatin analog injections for carcinoid syndrome have their own rhythm of care, with injections typically given every few weeks and periodic imaging to monitor disease stability. The emotional toll is real across all types: the rarity of many endocrine cancers means patients often feel isolated, struggling to find others who understand their diagnosis. Support networks specific to neuroendocrine tumors and thyroid cancer have expanded in recent years, but the experience of managing a chronic hormonal condition on top of cancer surveillance remains a significant quality-of-life concern that does not always get the attention it warrants.